Tarsus Pharmaceuticals Inc
NASDAQ:TARS

Watchlist Manager
Tarsus Pharmaceuticals Inc Logo
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
Watchlist
Price: 50 USD 0.06% Market Closed
Market Cap: 2.1B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
+55%
Operating Income
Forecast
N/A
Net Income
Forecast
+32%

Wall Street
Price Targets

TARS Price Targets Summary
Tarsus Pharmaceuticals Inc

Wall Street analysts forecast TARS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TARS is 70.23 USD with a low forecast of 46.46 USD and a high forecast of 89.25 USD.

TARS Lowest Forecast
Wall Street Target
46.46 USD
7% Downside
TARS Average Forecast
Wall Street Target
70.23 USD
40% Upside
TARS Highest Forecast
Wall Street Target
89.25 USD
79% Upside
Lowest
Price Target
46.46 USD
7% Downside
Average
Price Target
70.23 USD
40% Upside
Highest
Price Target
89.25 USD
79% Upside
Tarsus Pharmaceuticals Inc Competitors:
Price Targets
600750
Jiang Zhong Pharmaceutical Co Ltd
32% Upside
U
3933
United Laboratories International Holdings Ltd
17% Upside
COPN
Cosmo Pharmaceuticals NV
109% Upside
J
4015
Jamjoom Pharmaceuticals Factory Company SJSC
16% Upside
600750
Jiang Zhong Pharmaceutical Co Ltd
32% Upside
U
3933
United Laboratories International Holdings Ltd
17% Upside
COPN
Cosmo Pharmaceuticals NV
109% Upside
J
4015
Jamjoom Pharmaceuticals Factory Company SJSC
16% Upside
HYPE3
Hypera SA
4% Upside
NEULANDLAB
Neuland Laboratories Ltd
46% Upside
S
GPCR
Structure Therapeutics Inc
244% Upside

Revenue
Forecast

Revenue Estimate
Tarsus Pharmaceuticals Inc

The compound annual growth rate of Tarsus Pharmaceuticals Inc's revenue for the next 3 years is 58%.

N/A
Past Growth
58%
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Tarsus Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Tarsus Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
What are analyst estimates?

See Also

Summary
TARS intrinsic value, competitors valuation, and company profile.
DCF Valuation
TARS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TARS stock valuation using valuation multiples.
Wall Street Estimates
TARS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TARS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TARS's stock price target?
Price Target
70.23 USD

According to Wall Street analysts, the average 1-year price target for TARS is 70.23 USD with a low forecast of 46.46 USD and a high forecast of 89.25 USD.

What is Tarsus Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
58%

The compound annual growth rate of Tarsus Pharmaceuticals Inc's revenue for the next 3 years is 58%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.